TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07611214: PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Sponsor: Aurinia Pharmaceuticals Inc. · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,125,200

Rescue Site Savings

+$1,407,600

Unlock Full NCT07611214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07611214 Rescue Dossier →